ctDNA profiling was performed using the Tempus xF assay that can detect variants in 105 genes in the ctDNA fraction. When the researchers analysed NCCN indication-matched variants that were ...

Tempus AI announced a collaboration with the Institute for Follicular Lymphoma Innovation. The goal of the collaboration is to advance targeted therapy development for follicular lymphoma by ...

Tempus AI (NASDAQ:TEM) delivered a very mixed Q4 2024 earnings report that saw its shares sell off about 15% after hours. The main takeaway here is that Tempus' core business is expected to grow ...

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday ...